A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers
Study Details
Study Description
Brief Summary
This study is designed to evaluate the safety and immunogenicity of two monovalent Norovirus (NoV) oral tableted vaccine candidates, VXA-G1.1-NN and VXA-GII.4-NS co-administered (bivalent delivery) against a matching placebo arm. Bivalent GI.1 and GII.4 vaccines are being investigated for the prevention of noroviral gastroenteritis caused by norovirus GI.1 and GII.4.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Norovirus infections are a leading cause of sporadic and epidemic gastroenteritis across all age groups worldwide. This study is designed as a standard double-blind placebo-controlled single administration, dose ranging study to evaluate the safety and immunogenicity of 2 different doses of VXA-GII.4-NS plus VXA-G1.1-NN (high and medium dose administered orally for the prevention of Norovirus infection), compared with a placebo.
This study will enroll 10 sentinel subjects in an open label period and randomize 613 subjects in three arms.
The first 10 sentinel subjects will receive the open label high dose of active vaccine. If no dose-related toxicities are observed, and upon the recommendation of the SMC following review of safety data, subjects will be randomized in a 2:2:1 ratio to one of the 3 study arms to receive active vaccine or placebo. After vaccination on Day 1, the study will include an Active Study Period that runs through 4 weeks after administration (Day 29), and a Follow-up Period of one year for safety and duration of immune response.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Open Label Sentinel Bivalent GII.4/GI.1 vaccine Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets total dose is 2×10 to the power 11 IU/dose (sentinel n=10) |
Drug: Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose
The first 10 sentinel subjects will receive open label high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
|
| Experimental: Medium Dose Arm Bivalent GII.4/GI.1 vaccine Bivalent GII.4/GI.1 medium dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 5×10 to the power 10 tablets total dose is 1×10 to the power 11 IU/dose (N=245) |
Drug: Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose
245 subjects will receive Bivalent GII.4/GI.1 medium dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 5×10 to the power 10 tablets; total dose is 1×10 to the power 11 IU/dose
|
| Experimental: High Dose Arm Bivalent GII.4/GI.1 vaccine Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets total dose is 2×10 to the power 11 IU/dose (N=245) |
Drug: Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose
245 subjects will receive high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
|
| Placebo Comparator: Placebo Arm Placebo tablets (N= 123) |
Drug: Placebo
123 subjects will receive matching placebo
|
Outcome Measures
Primary Outcome Measures
- The safety of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Frequency, duration and severity of Solicited Symptoms of Reactogenicity (GI and systemic) [Up to 1 week]
- The safety of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Frequency, duration, and severity of unsolicited adverse events (AEs) [Up to 28 days]
- The safety of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Frequency, duration, and severity of serious adverse event (SAEs). [Up to 1 year]
- The safety of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Frequency, duration, and severity of adverse event of special interest (AESIs). [Up to 1 year]
- The safety of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Frequency, duration, and severity of New Onset of Chronic Illness (NOCIs). [Up to 1 year]
- The immunogenicity of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Geometric mean concentration (GMC) of Serum -Anti IgA for both vaccines [On Day 29]
- The immunogenicity of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Geometric mean fold rise (GMFR) of Serum -Anti IgA for both vaccines [Up to Day 29]
Eligibility Criteria
Criteria
Key Inclusion Criteria:
To be eligible for this study, subjects must meet all the following:
-
In stable and good general health, without significant medical illness, based on medical history, physical examination, and vital signs at screening based on investigator judgement.
-
Body mass index (BMI) between 17.0 and 35.0 kg/m2 at screening SNG.
-
Available for all planned visits and tele-health appointment, and willing to complete all protocol-defined procedures and assessments (including ability and willingness to swallow multiple small enteric-coated tablets per study dose).
-
Female subjects must not be breastfeeding and must provide a negative pregnancy test at screening and pre-dose.
-
Female subjects must fulfill one of the following criteria:
- At least 1 year post-menopausal (defined as amenorrhea for greater than or equal to 12 consecutive months prior to screening without alternative medical cause) or surgically sterile.
-
Female subjects of childbearing potential must be willing to use a highly effective form of contraception for 30 days prior to initial vaccination and until 60 days after last vaccination. Acceptable forms are oral, implantable, intrauterine, transdermal, intravaginal, injectable, double barrier or abstinence (subjects using diaphragms must also use condom). The form of contraception must be approved by the investigator.
-
Male subjects must agree to practice abstinence from heterosexual intercourse or to use an effective method of birth control as noted above from first vaccination to 60 days after last vaccination. Male subjects must agree to refrain from donating sperm and practice abstinence from all intercourse or to use an effective method of double barrier birth control or condom as noted above from first vaccination to 60 days after last vaccination.
- Capable of understanding and giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.
Key Exclusion Criteria:
The subjects must be excluded from participating in the study if they meet any of the following:
-
Known clotting/bleeding issues and/or personal and family history with increased risk of bleeding or clotting.
-
Presence of significant uncontrolled medical or psychiatric illness (acute or chronic) including institution of new medical/surgical treatment or significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months prior to screening and reconfirmed at baseline.
-
Cancer, or treatment for cancer or any procedure or preventive medication for cancer or to prevent recurrence, within past 3 years (excluding fully treated and resolved basal cell carcinoma or squamous cell carcinoma)
-
Presence of immunosuppression or medical condition possibly associated with impaired immune responsiveness, including diabetes mellitus- type 1 and 2
-
History of irritable bowel disease or other inflammatory digestive or gastrointestinal condition that could affect the distribution/safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine.
-
History of any form of angioedema
-
History of serious reactions to vaccination such as anaphylaxis, respiratory problems, hives or abdominal pain
-
Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws problematic
-
Any condition that resulted in the absence or removal of the spleen
-
Acute disease within 72 hours prior to vaccination defined as the presence of a moderate or severe illness (as determined by the investigator through medical history and physical exam). (Assessment may be repeated once during Screening Period)
-
Presence of a fever greater than or equal to 38°C measured orally at baseline.
-
Any significant hospitalization within the last year which in the opinion of the investigator or sponsor could interfere with study participation.
-
Any history or conditions that may lead to higher risk of clotting events and/or thrombocytopenia.
-
Positive human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg) or Hepatitis C virus (HCV) tests at the screening visit.
-
History of GI bleeding including hematochezia (blood in stool) or melena (black stool)
-
Positive urine drug screen for drugs of abuse at screening (positive test for marijuana is not exclusionary; however concurrent use of marijuana during the study Active period through Day 29 is prohibited).
-
Positive breath or urine alcohol test at screening and baseline.
-
Receipt of a licensed vaccine (including any COVID-19 vaccines under emergency use authorization) within 14 days prior to baseline vaccination or planned administration during the study active period (Day 29).
-
Use of antibiotics, proton pump inhibitors, H2 blockers or antacids within 7 days prior to study drug administration or planned use during the active study period (Day 29).
-
Use of medications known to affect the immune function (e.g., including but not limited to systemic corticosteroids, leukotriene modifiers, and JAK inhibitors) within 2 weeks before study drug administration or planned use during the active study period (Day 29).
-
Daily use of nonsteroidal anti-inflammatory drugs within7 days prior to study drug administration or planned use during the active study period (Day 29). Low dose daily ASA ≤ 100 mg for cardio-protection is not exclusionary.
-
Administration of any investigational vaccine, drug or device within 8 weeks preceding study drug administration, or planned use within the duration of the study
-
Previous participation in a Vaxart Clinical Trial or other NoV vaccine trial unless confirmed receipt of placebo.
-
Donation or use of blood or blood products within 30 days prior to study drug administration or planned donation during the active study period (Day 29).
-
History of drug, alcohol, or chemical abuse within 1 year of screening.
-
History of hypersensitivity or allergic reaction to any component of the investigational vaccine, including but not limited to fish gelatin allergy.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Velocity Clinical Research | La Mesa | California | United States | 91942 |
| 2 | Ark Clinical Research | Long Beach | California | United States | 90806 |
| 3 | Jacksonville Center for Clinical Research, Inc | Jacksonville | Florida | United States | 32216 |
| 4 | Johnson County Clin-Trials | Lenexa | Kansas | United States | 66219 |
| 5 | Pharmaron Clinical Research | Baltimore | Maryland | United States | 21201 |
| 6 | Nucleus Network Pty Ltd | Saint Paul | Minnesota | United States | 55114 |
| 7 | AMR Kansas City | Kansas City | Missouri | United States | 64114 |
| 8 | Rochester Clinical Research, Inc | Rochester | New York | United States | 14609 |
| 9 | NZCR Auckland: New Zealand Clinical Research OpCo Ltd. | Grafton | Auckland | New Zealand | 1010 |
| 10 | Optimal Auckland | Grafton | Auckland | New Zealand | 1010 |
| 11 | P3 Research Hawke's Bay | Havelock North | Hawke's Bay | New Zealand | 4130 |
| 12 | P3 Research Lower Hutt | Lower Hutt | Hutt Central | New Zealand | 5010 |
| 13 | NZCR Christchurch: New Zealand Clinical Research OpCo Ltd. | Christchurch | New Zealand | 8011 |
Sponsors and Collaborators
- Vaxart
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- VXA-NVV-202